FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033623135> ?p ?o ?g. }

• W3033623135 abstract "Abstract Background and Aims Steroid therapy is efficient in inducing remission of IgA nephropathy (IgAN) and preventing end stage renal disease (ESRD) but there are concerns about their safety. The TESTING trial in particular has been stopped early because of a higher incidence of side effects than conservative treatment thus inducing a conservative therapy with RAAS (renin angiotensin antagonist system) blockers. The aim of this analysis was to evaluate the incidence of adverse events (AE) in a retrospective observational trial on the real clinical practice. Method We evaluated 1209 patients (pz) with IgAN coming from 48 Italian centers: 285 pz in RAAS blockers alone, 732 treated for 6 months with steroid and 192 with a combination of steroid and other immunosuppressants (also with RAAS blockers). The analysis was limited to the 6 months of therapy. Results The basal characteristics of the 3 groups are shown in the table below. The figure shows the frequencies of 69 adverse events related with immunosuppression: the most frequent were infections (23, 2.73% of all patients, 34.3% of all AE), impaired glycemic control (11, 0.91% of patients, 16% of all AE), severe hypertension (6, 8.7% of all AE) and leukopenia (9, 0.80% of patients, 13% of all AE). Infections were observed in 16 (2.19%) pz in steroid therapy and 7 (3.65%) pz in steroid+immunosoppressive treatment. Liver toxicity and and gastrointestinal AE were observed almost in pz receiving steroid+ immunosuppressants [1(0.14%) and 2 (1.04%) pz, respectively]. 7 pz in steroid therapy (0.96%) and 2 in steroid+ immunosuppressants experienced an impaired glycemic control. All the 9 cases of leucopenia were registered in pz in steroid+ immunosuppressants (4.69%). A slightly higher incidence of allergies was observed in the RAAS blocker group (20 cases, 0.7%). The higher rates of infections and leucopenia were observed in pz above 70 years of age (6.12%,p&lt;0.05), as higher incidence of infections and impaired glycemic control were registered in pz with an eGFR&lt;30 ml/min/1.73 m2 (4.64 and 1.99%,p&lt;0.05). Severe hypertension and leucopenia were observed respectively in 9 and 3 pz with an eGFR &lt;60 ml/min/1.73m2. No significant relationships were found between AE, proteinuria and sex. Multivariate logistic regression showed an independent association of immunosuppressive treatment and age with any AE [ODDS ratio: 3,35 (CI:2,18-5,14) and 1,02 (CI:1,01-1,04), respectively; p&lt;0.05]. Death occurred for sepsis in a 70 years old pz (eGFR=21.7 ml/min/m2, 24hproteinuria=16.1 g/day) after 3 months of treatment. Conclusion the incidence of EA in our observational study is lower than that observed in the TESTING and STOP trials (5.71% vs 14.7% and 40%, respectively). The most frequent AE were almost observed in oldest subjects with impaired renal function on steroid+other immunosuppressants. Though this trial is not randomized nor controlled (RC), it considers a large cohort of pz coming from the real clinical practice of the Italian Nephrology Units and demonstrates that the significantly lower incidence of steroid related AE than that observed in some RC trials doesn’t justify the abstention from steroids in IgAN at risk of progression. Much more attention should be paid in elderly pts with severe renal dysfunction with a closer follow-up, dose adjustments and antibiotic prophilaxis." @default.
• W3033623135 created "2020-06-12" @default.
• W3033623135 creator A5012034101 @default.
• W3033623135 creator A5015681668 @default.
• W3033623135 creator A5027115613 @default.
• W3033623135 creator A5030398223 @default.
• W3033623135 creator A5031273565 @default.
• W3033623135 creator A5031521563 @default.
• W3033623135 creator A5036668173 @default.
• W3033623135 creator A5051735479 @default.
• W3033623135 creator A5057407225 @default.
• W3033623135 creator A5077169554 @default.
• W3033623135 creator A5079456233 @default.
• W3033623135 creator A5082570419 @default.
• W3033623135 creator A5077865983 @default.
• W3033623135 date "2020-06-01" @default.
• W3033623135 modified "2023-10-11" @default.
• W3033623135 title "P0366SAFETY OF STEROID THERAPY IN IGA NEPHROPATHY: THE CLINICAL EXPERIENCE OF 48 NEPHROLOGY UNITS IN ITALY" @default.
• W3033623135 doi "https://doi.org/10.1093/ndt/gfaa142.p0366" @default.
• W3033623135 hasPublicationYear "2020" @default.
• W3033623135 type Work @default.
• W3033623135 sameAs 3033623135 @default.
• W3033623135 citedByCount "0" @default.
• W3033623135 crossrefType "journal-article" @default.
• W3033623135 hasAuthorship W3033623135A5012034101 @default.
• W3033623135 hasAuthorship W3033623135A5015681668 @default.
• W3033623135 hasAuthorship W3033623135A5027115613 @default.
• W3033623135 hasAuthorship W3033623135A5030398223 @default.
• W3033623135 hasAuthorship W3033623135A5031273565 @default.
• W3033623135 hasAuthorship W3033623135A5031521563 @default.
• W3033623135 hasAuthorship W3033623135A5036668173 @default.
• W3033623135 hasAuthorship W3033623135A5051735479 @default.
• W3033623135 hasAuthorship W3033623135A5057407225 @default.
• W3033623135 hasAuthorship W3033623135A5077169554 @default.
• W3033623135 hasAuthorship W3033623135A5077865983 @default.
• W3033623135 hasAuthorship W3033623135A5079456233 @default.
• W3033623135 hasAuthorship W3033623135A5082570419 @default.
• W3033623135 hasBestOaLocation W30336231351 @default.
• W3033623135 hasConcept C120665830 @default.
• W3033623135 hasConcept C121332964 @default.
• W3033623135 hasConcept C126322002 @default.
• W3033623135 hasConcept C134018914 @default.
• W3033623135 hasConcept C197934379 @default.
• W3033623135 hasConcept C2778653478 @default.
• W3033623135 hasConcept C2780252810 @default.
• W3033623135 hasConcept C2780873365 @default.
• W3033623135 hasConcept C2781184683 @default.
• W3033623135 hasConcept C29730261 @default.
• W3033623135 hasConcept C54847362 @default.
• W3033623135 hasConcept C555293320 @default.
• W3033623135 hasConcept C61511704 @default.
• W3033623135 hasConcept C71924100 @default.
• W3033623135 hasConcept C90924648 @default.
• W3033623135 hasConceptScore W3033623135C120665830 @default.
• W3033623135 hasConceptScore W3033623135C121332964 @default.
• W3033623135 hasConceptScore W3033623135C126322002 @default.
• W3033623135 hasConceptScore W3033623135C134018914 @default.
• W3033623135 hasConceptScore W3033623135C197934379 @default.
• W3033623135 hasConceptScore W3033623135C2778653478 @default.
• W3033623135 hasConceptScore W3033623135C2780252810 @default.
• W3033623135 hasConceptScore W3033623135C2780873365 @default.
• W3033623135 hasConceptScore W3033623135C2781184683 @default.
• W3033623135 hasConceptScore W3033623135C29730261 @default.
• W3033623135 hasConceptScore W3033623135C54847362 @default.
• W3033623135 hasConceptScore W3033623135C555293320 @default.
• W3033623135 hasConceptScore W3033623135C61511704 @default.
• W3033623135 hasConceptScore W3033623135C71924100 @default.
• W3033623135 hasConceptScore W3033623135C90924648 @default.
• W3033623135 hasLocation W30336231351 @default.
• W3033623135 hasOpenAccess W3033623135 @default.
• W3033623135 hasPrimaryLocation W30336231351 @default.
• W3033623135 hasRelatedWork W11602846 @default.
• W3033623135 hasRelatedWork W17661181 @default.
• W3033623135 hasRelatedWork W19849252 @default.
• W3033623135 hasRelatedWork W19878240 @default.
• W3033623135 hasRelatedWork W2700549 @default.
• W3033623135 hasRelatedWork W2753835 @default.
• W3033623135 hasRelatedWork W2857627 @default.
• W3033623135 hasRelatedWork W3684279 @default.
• W3033623135 hasRelatedWork W7996314 @default.
• W3033623135 hasRelatedWork W9199247 @default.
• W3033623135 isParatext "false" @default.
• W3033623135 isRetracted "false" @default.
• W3033623135 magId "3033623135" @default.
• W3033623135 workType "article" @default.